Missouri Attorney General sends cease-and-desist letter to Eli Lilly and Company after a dispute with University of Missouri Health Care over prescription drug pricing and access to federal 340B discounts. Attorney General Catherine Hanaway announced the action in the latest update on October 26, 2026, demanding that the pharmaceutical manufacturer stop requiring Missouri hospitals to submit extensive claims data as a condition of obtaining discounted medications.
The dispute centers on the federal 340B Drug Pricing Program, which helps eligible healthcare providers purchase certain outpatient medications at reduced prices. Missouri officials argue that Eli Lilly’s policy places hospitals in a difficult position by tying access to those discounts to the disclosure of sensitive patient claims information.
The University of Missouri Health Care system, commonly known as MU Health Care, became directly involved after it refused to comply with the company’s policy. Eli Lilly subsequently cut off the health system’s access to its 340B pricing on July 2, 2026.
MU Health Care later agreed to provide the requested information temporarily to avoid further financial losses and potential harm to patients, while reserving its rights. Hanaway’s cease-and-desist letter now challenges the company’s requirements and warns that failure to comply could lead to legal enforcement.
What Prompted the Missouri Attorney General’s Action?
The disagreement arose after Eli Lilly introduced a policy requiring hospitals participating in the 340B program to submit detailed claims data for every dispensing of a Lilly product, regardless of the setting in which the medication was provided.
MU Health Care refused to provide the requested information. The health system’s position brought it into conflict with the pharmaceutical manufacturer, which then removed its access to the applicable 340B pricing.
The loss of discounted pricing created a financial concern for the health system. Hospitals participating in the program depend on reduced medication costs to manage expenses and support services for patients who need affordable healthcare.
MU Health Care eventually agreed to submit the information temporarily to limit additional financial losses and reduce the risk of harm to patients. However, the health system reserved its rights, meaning the temporary arrangement did not necessarily settle the underlying disagreement.
Hanaway’s office subsequently challenged the policy, arguing that hospitals should not have to surrender extensive claims information to obtain discounted prices available through the federal program.
The attorney general’s intervention brings the dispute into the state’s consumer protection framework. It also raises questions about the conditions pharmaceutical manufacturers can impose on eligible hospitals seeking access to 340B pricing.
What the Cease-and-Desist Letter Demands
The cease-and-desist letter directs Eli Lilly to end the disputed claims-data submission requirement for Missouri hospitals seeking 340B pricing. It also demands that the company stop using claims data collected under the policy.
Hanaway argues that the manufacturer has used its market position to impose conditions that interfere with hospitals’ access to discounted prescription drugs. The state maintains that eligible healthcare providers should not lose access to applicable prices because they refuse to supply information that officials consider unnecessary.
The letter focuses on several key demands:
- End the disputed data requirement: Eli Lilly must stop conditioning access to 340B pricing in Missouri on the challenged claims-data submission policy.
- Stop using collected information: The company is directed to discontinue the use of claims data obtained under that policy.
- Address the state’s legal concerns: The manufacturer is being told to stop the practices that the attorney general considers unlawful.
- Avoid further enforcement: Failure to comply could lead to an enforcement action under Missouri’s consumer protection law.
The letter represents an official demand from the attorney general. It does not, by itself, establish that a court has ruled against Eli Lilly or ordered the company to pay penalties.
The next important development will be whether the manufacturer changes its policy, contests the state’s position, or faces additional legal proceedings.
Understanding the Federal 340B Drug Pricing Program
The 340B Drug Pricing Program is a federal initiative established in 1992. It requires participating drug manufacturers to offer covered outpatient medications at reduced prices to eligible healthcare organizations.
The program helps qualifying hospitals and other providers stretch limited resources while serving patients who may have difficulty affording medical treatment. Eligible organizations include certain hospitals, community health centers, and specialized healthcare facilities.
For participating hospitals, the savings on covered medications can help support patient services and manage the cost of providing care. The program is especially important for providers that serve low-income and uninsured populations.
The 340B program does not mean that every prescription is free or that every patient automatically receives the same discount at the pharmacy counter. Instead, it establishes a purchasing framework that allows eligible organizations to obtain covered outpatient medications at reduced prices.
Participating providers must also follow applicable program requirements. These include maintaining appropriate records, meeting eligibility conditions, and avoiding duplicate discounts prohibited under federal rules.
The Missouri dispute concerns the relationship between those federal pricing requirements and Eli Lilly’s additional claims-data policy. Hanaway’s office argues that the company cannot use access to discounted medications to compel hospitals to accept conditions that violate applicable law.
The outcome could influence how similar disagreements over pricing conditions and data requirements are handled in Missouri.
Why MU Health Care Is Central to the Dispute
MU Health Care’s experience illustrates the practical consequences of the disagreement.
When the health system declined to submit the information requested by Eli Lilly, it lost access to the company’s 340B pricing on July 2. That decision affected the purchasing arrangements available to the provider for the medications covered by the policy.
The health system later agreed to supply the information temporarily to avoid further financial losses and potential harm to patients. It also reserved its rights, leaving room to challenge the policy.
The temporary agreement does not establish that MU Health Care permanently accepted the company’s requirements. It also does not mean the broader dispute has been resolved.
For hospitals, discounted medication purchasing can be an important part of managing healthcare expenses. Losing those discounts may increase acquisition costs for affected products, although the specific financial consequences depend on the medications involved and the provider’s purchasing arrangements.
Hanaway argues that hospitals should not have to choose between providing information they consider unnecessary and maintaining access to discounted medications.
Her intervention seeks to change the conditions that created that dilemma. It also places the state’s legal concerns over patient information and prescription pricing at the center of the disagreement.
How Missouri’s Consumer Protection Law Applies
The attorney general has identified the Missouri Merchandising Practices Act as a possible basis for further enforcement against Eli Lilly.
The law addresses certain unfair and deceptive practices in trade or commerce. Missouri authorities can use it to investigate and challenge business conduct that falls within its scope.
Hanaway’s office argues that the company’s policy may mislead consumers by representing that eligible hospitals can obtain federally required 340B prices while imposing a data-submission condition that can prevent them from accessing those prices.
The state also maintains that the policy uses the company’s market position to pressure healthcare providers into disclosing extensive claims information.
These statements represent the attorney general’s legal position. Whether the policy violates Missouri law would depend on the applicable legal standards and any further proceedings.
The cease-and-desist letter warns that failure to comply could result in an enforcement action under the Missouri Merchandising Practices Act.
As of the latest confirmed update, the letter has been issued, but no final court judgment resolving the dispute has been established by the announcement.
Why the Dispute Matters for Rural Hospitals
Missouri’s attorney general has emphasized that rural hospitals rely on the 340B program to maintain important healthcare services.
Facilities in rural communities may operate with limited financial resources while treating patients who have fewer nearby alternatives for medical care. Savings from discounted medications can help eligible providers maintain services and direct resources toward patient needs.
The program can help support emergency departments, cancer treatment services, clinics, and care for low-income or uninsured patients. Its importance varies among organizations, depending on their eligibility, patient populations, and healthcare operations.
When a hospital loses access to applicable discounts, its costs for affected medications may increase. Additional expenses can create pressure on budgets already covering staffing, equipment, facilities, and other essential services.
However, the attorney general’s announcement does not quantify the specific financial losses associated with MU Health Care’s dispute. It also does not establish that every hospital in Missouri has experienced the same problem.
Hanaway’s concern is that pharmaceutical companies’ pricing conditions could create broader obstacles for eligible providers that depend on the program.
The dispute therefore extends beyond one health system. Its resolution may help clarify how hospitals and manufacturers address disagreements over access to discounted medications and claims-data requirements.
What the Dispute Means for Patients and Prescription Costs
Patients may wonder whether the cease-and-desist letter will change their prescription prices or affect their ability to receive treatment.
The announcement concerns access to discounted drug purchasing for eligible healthcare organizations. It does not announce a general price increase for all Eli Lilly medications or confirm that every patient in Missouri will pay more for prescriptions.
The effect on an individual patient depends on several factors, including the medication, insurance coverage, provider arrangements, and applicable pharmacy pricing.
If a hospital faces higher acquisition costs for certain medications, it may experience additional financial pressure. However, the announcement does not establish a specific increase in patient bills or out-of-pocket expenses.
The attorney general’s stated goal is to protect access to discounted medications and challenge pricing conditions that the state believes undermine the purpose of the 340B program.
Patients should not assume that their current prescriptions have changed in price or that their treatment has been interrupted because of the announcement.
The state has not announced a universal patient refund, a specific compensation amount, or an across-the-board reduction in prescription prices as part of this action.
What Happens Next in the Eli Lilly Dispute?
Eli Lilly’s response to the cease-and-desist letter will be an important next development.
The company could revise the disputed policy, engage with state officials, or contest Missouri’s legal interpretation. These are possible outcomes, not confirmed actions.
Hanaway has warned that the state may pursue further enforcement if the manufacturer does not comply with the demands.
Any subsequent legal proceedings would need to consider the company’s policy, the applicable federal 340B requirements, the relevant facts, and Missouri’s authority to pursue claims under its consumer protection law.
The dispute involves both federal and state legal questions. The 340B program operates under federal law, while Missouri is asserting that the challenged conduct also raises concerns under state law.
The current announcement does not establish that federal authorities have issued a final ruling on this particular dispute. It also does not confirm that Eli Lilly has withdrawn the policy nationwide.
The confirmed developments are the loss of MU Health Care’s 340B pricing in July, the health system’s temporary agreement to provide data while reserving its rights, and the attorney general’s cease-and-desist action announced on October 26, 2026.
Claims that the dispute has been settled, that penalties have been imposed, or that a court has ordered a particular remedy would require additional confirmation.
How Missourians Can Report Suspected Unfair Pharmaceutical Practices
Missourians who believe they have experienced unfair pharmaceutical business practices can file a consumer complaint with the Missouri Attorney General’s Office.
Residents should describe what happened and provide relevant documentation when available. Clear details can help officials assess the complaint and determine whether further review may be appropriate.
Submitting a complaint does not automatically establish that a company violated the law. It also does not guarantee a refund, compensation, or a change in prescription prices.
The attorney general’s announcement does not establish a special compensation program for patients affected by the MU Health Care dispute.
Residents should distinguish between personal experiences and assumptions about the broader policy. They should also avoid sharing unnecessary sensitive medical information when reporting a concern.
Latest Update on the Missouri Attorney General’s Cease-and-Desist Letter
The latest confirmed development is that Attorney General Catherine Hanaway issued a cease-and-desist letter to Eli Lilly on October 26, 2026.
The action follows the manufacturer’s decision to cut off MU Health Care’s access to 340B pricing after the health system declined to provide the requested claims data. MU Health Care later agreed to submit the information temporarily while reserving its rights.
Hanaway is demanding that Eli Lilly end the disputed data-submission requirement in Missouri and stop using information collected under the policy. The attorney general has warned that failure to comply could result in further legal action.
The central question is whether the manufacturer’s conditions unlawfully restrict eligible hospitals’ access to discounted prescription medications.
The letter marks a significant escalation in the dispute, but it does not establish a final legal resolution. The company’s response and any subsequent enforcement proceedings will determine how the matter develops.
What do you think about Missouri’s effort to protect hospital access to discounted prescription drugs? Share your thoughts in the comments and stay tuned for verified updates on this developing dispute.
Meta Description: Missouri Attorney General sends cease-and-desist letter to Eli Lilly over 340B drug pricing conditions affecting MU Health Care.
Tags: Missouri Attorney General, cease-and-desist letter, Eli Lilly, MU Health Care, 340B Drug Pricing Program, prescription drug prices, Catherine Hanaway, Missouri healthcare, pharmaceutical pricing, hospital drug discounts,